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Introduction
Several aspects of asthma heterogeneity both from a clinical 
and pathophysiological perspective remain still unclear. A 
number of treatment options have been developed over time, 
from the widely used corticosteroids to personalized approaches, 
including recently introduced biological therapies. The new 
classification of severe asthma is based on endotypes, whose 
definition relies on the features of the underlying inflamma-
tion. The endotypes define traditional phenotypes by describ-
ing their pathophysiological mechanisms1,2. Exploring endotypes 
and phenotypes require the identification of specific molecu-
lar targets, which can be addressed by precision treatments 
such as biologic drugs. The management of severe asthma is 
benefitting from personalized medicine approaches based on the 
characterization of an increasing number of endotypes, which 
represent the targets of specific therapies3. These are mainly 
represented by the Th2-high subtype and the Th2-low subtype, 
characterized by the presence of eosinophilic or neutrophilic/
paucigranulocytic airway inflammation respectively3. Currently 
targeted therapies for a number of Th2 – low endotypes are still 
lacking4. For this and other reasons, the need for increasing 
the effectiveness of personalized therapies opens the field to the 
omics approaches.
New asthma phenotyping has led to a growing interest in 
targeted therapies. The search for new pharmacological targets 
has caused interest in understanding the pathophysiological and 
molecular mechanisms underlying asthma. So far, the majority 
of the available drugs target the Th2-cytokine pathway5.
What else could be done for the management of severe 
asthma
Omics technology supports precision medicine in identifying 
the most effective treatment for different clinical phenotypes, in 
contrast with the “one size fits all” approach. Indeed, omics sci-
ences contribute to the definition of new biomarkers, which can 
be useful as hallmarks of a specific asthma endotype or pheno-
type, and relevant as novel targets for pharmacology treatments. 
In the field of molecular biology, omics is a neologism that indi-
cates high-throughput experimental technologies providing the 
tools for comprehensively monitoring the disease processes at a 
molecular level. The suffix “ome” comes from “chromosome” 
and currently includes several biological fields such as genom-
ics, transcriptomics, proteomics, metabolomics and epigenomics. 
Genomics and transcriptomics have been using to identify genes 
associated with asthma severity (Figure 1). Recent genome-wide 
association studies (GWAS) have shed light on distinct pathways 
that contribute to asthma inflammation. Genes such as HLA, IL13, 
IL33, thymic stromal lymphopoietin (TSLP) involved in Th2 
pathway, IL-1 receptor–like 1 (IL1RL1), encodes ST2, and the 
receptor for IL-33 are associated with asthma onset. In contrast, 
it is well-known that the risk of childhood asthma is associ-
ated with the 17q21 locus encoding the ORMDL3 and GSDML 
genes6,7. Transcriptomics are focused on the identification of 
an increasing number of several types of RNA with different 
function, e.g messenger RNAs (mRNAs) and long non coding 
RNAs (lncRNAs) but particular attention should be given to the 
investigation of microRNAs (miRNAs). MiRNAs are small non-
coding single strand RNA chains involved in post-transcriptional 
regulation processes. MiRNAs play a key role in regulat-
ing cell functions as well as in modulating the inflammatory 
pathways. They may influence the single endotype profile 
in the complex asthma phenotype picture, therefore, the rel-
evance of miRNA as a biomarker has been increasingly inves-
tigating. MiRNAs can be collected through peripheral blood 
sampling (Circulating miRNA), or, more invasively, through 
bronchial biopsies and induced sputum8,9. Circulating miRNA 
deserves a specific interest, because they might be a non- 
invasive biomarker useful in asthma diagnosis and charac-
terisation, as demonstrated in a recent study. According to the 
authors, a specific subset of circulating miRNAs (miR-125b, 
miR-16, miR-299-5p, miR-126, miR-206, and miR-133b) was 
found in patients with allergic rhinitis and asthma10. MiRNA 
192 in peripheral blood was under-expressed in blood of 
asthmatic patients underwent an allergen inhalation challenge11. 
Different levels of miR-1248 in serum of asthmatic vs non-
asthmatic patients have been also documented. MiR-1248 is 
involved in the regulation of IL-5 pathway11.
Epigenomics includes DNA methylation, histone modifications 
and non-coding RNAs previously described. Its role is to control 
gene expression acting on DNA structure. Several genes related 
to asthma are regulated by epigenetic mechanism such as genes 
involved in T-effector pathways (Interferon INF-γ, Ιnterleukin 
(IL)-4, IL-13 and IL-17), T-regulatory pathways (forkhead 
box P3 [FoxP3]) and airway inflammation (arginase [ARG])12. 
The “methylome” (the set of DNA methylation patterns) has 
been increasingly investigating through highly sophisticated 
sequence-based assays. Epigenetic mechanisms could lead to the 
identification of new asthma biomarkers. Recently, an epi-
genetic association between serum IgE concentration and 
methylation at different loci derived from DNA of leukocites 
has been described. Methylation at these CpG islands differed 
significantly in isolated eosinophils between subjects with and 
without asthma and high IgE levels13.
Modern and advanced technologies, such as mass spectrometry, 
allow the detection of several proteins involved in the inflam-
matory mechanisms of asthma. Today several biomarkers 
can identify Th2-high endotypes (serum IgE, serum perios-
tin, blood eosinophil, exhaled nitric oxide eNO, dipeptidyl 
peptidase 4 (DPP-4 serum) in sputum. Among the proteom-
ics signatures characterized so far, Galectin-3 deserves to be 
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Figure 1. A systems biology approach: From omics science to precision medicine.
mentioned. It was indeed demonstrated that this protein is 
expressed in omalizumab responders only. Furthermore, galec-
tin–3 seems to be associated with a more evident improve-
ment of respiratory function in asthmatic patients treated with 
omalizumab14.
The increasing interest in metabolomics, is mainly due to its 
prospective clinical applications. Metabolomics could play an 
important role in measuring the concentrations of the metabo-
lites generated in living system. According to recent findings 
it is possible to define the metabolic profile through different 
matrix including exhaled breath, urine, plasma and serum15,16, 
Exhaled breath condensate (EBC) is a promising tool for 
the detection of asthma biomarkers. This biological sample 
could be used as a natural matrix of the respiratory tract, 
carrying useful biomarkers which allow to monitor changes in 
inflammatory airways diseases17. As recently demonstrated, elec-
tronic nose (eNose) and nuclear magnetic resonance (NMR)-
based metabolomics could play a role in phenotyping chronic 
airway disease regardless of the diagnosis of asthma or COPD, 
suggesting therapeutical targets for a tailored respiratory 
medicine18. EBC contains different inorganic molecular species 
such as nitric oxide (NO) and carbon monoxide (CO) and also 
volatile organic compounds. Currently a branch of metabolomics 
called “breathomics” focuses on VOCs from the respiratory 
tract. VOCs represent potential non-invasive metabolic biomark-
ers, particularly in the diagnosis and monitoring of pulmonary 
diseases including asthma19. Moreover, an electronic nose able 
to discriminate asthmatic from healthy controls by detecting 
different VOCs in exhaled breath has been developed19,20. 
Therefore, metabolomics could play a key role in identifying 
biomarkers and improving asthma endotyping.
Conclusion
The application of omics technology in asthma is follow-
ing other research fields, such as oncology21. Similarly, mono-
clonal antibodies (mAbs) for severe asthma have been recently 
introduced, while biological therapies addressing rheumatic 
diseases, solid tumors and blood cancer arrived more than a 
decade before. From 2006 to 2017 omalizumab was the only avail-
able treatment for severe allergic asthma. Only in recent years 
research and knowledge on new drugs has been developed to 
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achieve new and more effective therapeutic options22. Despite 
an increasing interest in omics technologies, none of the omics 
signatures mentioned above have been translated into clinical 
practice. We believe that there is an urgent need for large-scale 
studies. Particularly, specific Randomized Controlled Trials 
would be necessary to definitively confirm the clinical relevance 
of omics and reinforcing omics’ role in searching for new biomar-
kers and prognostic factors. The need for correctly selecting the 
right mAb for the right patient is one of the key points in severe 
asthma management. The real challenge for researchers and 
clinicians in the “omics era” is therefore translating acquired 
knowledge into clinical practice in order to emphasize omics’ 
role in precision medicine and to predict response to treatments. 
Unfortunately, in our opinion we are still far from that scenario.
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